Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.
Circulating plasma cells in 10 cases of reactive plasmacytosis had a shared phenotype with early plasma cell (CD19(+) CD38(+) CD138(+) CD40(+) CD45(+) CD11a+ CD49e- CD56(-)). In most cases, a minor subpopulation of CD28(+) plasma cells was also detected. Reactive plasma cells were highly proliferative, suggesting the presence of circulating progenitors (plasmablasts). After CD138(+) plasma cell removal, highly proliferative CD138(-) plasmablasts differentiated into CD138(+) plasma cells within a few days. This differentiation, which was associated with increased CD38 and decreased HLA-DR expression, was further confirmed by a large increase in intracellular Ig content (associated with Ig secretion) and was concomitant with extensive secretion of interleukin-6 (IL-6). The addition of neutralizing anti-IL-6 and anti-CD126 (IL-6 receptor) monoclonal antibodies totally prevented Ig secretion and cell differentiation by inducing apoptosis of plasmablasts, which indicates that IL-6 is an essential survival factor for plasmablasts. This report provides the first characterization of normal plasmablasts and shows that their phenotype is not exactly that of multiple myeloma cells.
INSERM U463, Laboratoire Central d'Hématologie, Institut de Biologie, Service d'Hématologie Clinique, Hôtel-Dieu, Nantes, France.
G
G
Jego
N
N
Robillard
D
D
Puthier
M
M
Amiot
F
F
Accard
D
D
Pineau
J L
JL
Harousseau
R
R
Bataille
C
C
Pellat-Deceunynck
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis; D017209:Apoptosis / Q000187:drug effects; D002454:Cell Differentiation; D002478:Cells, Cultured; D002648:Child; D005260:Female; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000473:pathology*; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D007146:Immunoglobulin lambda-Chains / Q000032:analysis; D016130:Immunophenotyping; D015850:Interleukin-6 / Q000276:immunology / Q000502:physiology; D008218:Lymphocytosis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology; D010950:Plasma Cells / Q000737:chemistry / Q000473:pathology*; D019947:Receptors, Interleukin-6 / Q000276:immunology / Q000502:physiology; D012075:Remission, Spontaneous; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D015850:Interleukin-6; D019947:Receptors, Interleukin-6